Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONC | CLUSTER | neutral | 2/10 | BeOne Medicines Ltd. (ONC) insiders executed a small cluster of open-market sales totaling $1.49M over eight days, led b | Jun 10, 2026 |
| TNGX | 424B5 | mixed | 6/10 | Tango Therapeutics is raising approximately $566.5 million in net proceeds through a public offering of 18,166,667 share | Jun 10, 2026 |
| XOMAP | DEFM14A | bullish | 8/10 | XOMA Royalty filed its definitive proxy statement on Schedule 14A, setting a special stockholder meeting for July 13, 20 | Jun 10, 2026 |
| TRDA | 8-K | neutral | 2/10 | Entrada Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Stockholders approve | Jun 10, 2026 |
| SNDX | 8-K | neutral | 5/10 | Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a pr | Jun 10, 2026 |
| IDYA | 8-K | bearish | 6/10 | IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares of common stock and | Jun 10, 2026 |
| VTVT | DEFA14A | neutral | 3/10 | vTv Therapeutics filed a DEFA14A to correct an inadvertent omission from its 2026 proxy statement, adding an advisory vo | Jun 10, 2026 |
| IOVA | 8-K | bullish | 7/10 | Iovance Biotherapeutics received marketing authorization from the Australian TGA for Amtagvi (lifileucel) for advanced m | Jun 10, 2026 |
| SNSE | S-3/A | neutral | 4/10 | Sensei Biotherapeutics filed Amendment No. 2 to its S-3 shelf registration to register 24,868,028 common shares for resa | Jun 10, 2026 |
| SNSE | 8-K | neutral | 3/10 | Sensei Biotherapeutics filed an 8-K reporting the results of its June 10, 2026 annual meeting. Stockholders approved the | Jun 10, 2026 |
| LQDA | 144 | bearish | 5/10 | Canaan VIII LP, a director and venture investor, filed a Form 144 to sell 200,000 shares of Liquidia Corp (LQDA) worth a | Jun 10, 2026 |
| TNGX | 144 | neutral | 2/10 | Director Daniella Beckman filed a Form 144 notice of intent to sell 4,446 shares of Tango Therapeutics common stock, wit | Jun 10, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | A small insider selling cluster at United Therapeutics (UTHR) saw the CEO, CFO, and EVP/GCO sell a combined ~$1.23M in o | Jun 10, 2026 |
| ANAB | 144 | bearish | 5/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 10, 2026, indicating intent to sell 20,000 shares (~$1 | Jun 10, 2026 |
| HUMAW | 8-K | bullish | 7/10 | Humacyte reported positive interim results from its V012 Phase 3 study of the ATEV in female dialysis access patients, d | Jun 10, 2026 |
| NUVL | CLUSTER | neutral | 3/10 | Nuvalent CEO James Porter exercised 30,000 options at $18.93/share and sold 12,495 shares on the open market for $1.1M, | Jun 10, 2026 |
| VIR | 8-K | neutral | 2/10 | Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee Chair, expanding the | Jun 10, 2026 |
| EIKN | 8-K | neutral | 2/10 | Eikon Therapeutics appointed Ma. Fatima D. Francisco as a Class I director effective June 15, 2026, with standard non-em | Jun 10, 2026 |
| ABEO | 8-K | neutral | 2/10 | Abeona Therapeutics filed an 8-K furnishing an updated investor presentation (Exhibit 99.1) under Item 7.01 for use in m | Jun 10, 2026 |
| LBRX | 8-K | neutral | 3/10 | Chief Medical Officer Anna Eramo, M.D. resigned effective June 15, 2026, for personal reasons, and will transition to a | Jun 10, 2026 |
| HUMA | PRESS-RELEASE | bullish | 7/10 | Humacyte announced positive top-line interim results from the V012 Phase 3 study of its acellular tissue engineered vess | Jun 10, 2026 |
| CLDX | PRESS-RELEASE | neutral | 4/10 | Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold | Jun 10, 2026 |
| HYFT | 6-K | neutral | 4/10 | MindWalk Holdings Corp. launched ReefIQ, a biological context layer for AI drug discovery that sits between client disco | Jun 10, 2026 |
| AIM | 424B5 | bearish | 7/10 | AIM ImmunoTech is conducting a best-efforts registered direct offering of 2,554,119 shares at $0.5189/share (~$1.33M gro | Jun 10, 2026 |
| BGMSP | 8-K | bearish | 5/10 | On June 10, 2026, Bio Green Med Solution raised gross proceeds of $794,403 through a Regulation S private placement, iss | Jun 10, 2026 |
| MBX | 144 | neutral | 2/10 | Richard Bartram, a former officer of MBX Biosciences, filed a Form 144 on June 10, 2026, signaling intent to sell 9,167 | Jun 10, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva closed its acquisition of Emalex Biosciences for $700M upfront plus up to $200M in milestones and sales-based royal | Jun 10, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's files a routine 6-K announcing management participation in an Investec investor conference in London on June | Jun 10, 2026 |
| MGX | CLUSTER | neutral | 2/10 | Two insiders (both See Remarks) sold a combined $5,579 in open-market sales on June 5, 2026, at $1.299/share. The aggreg | Jun 10, 2026 |
| PFE | ANALYST-UPGRADE | neutral | 2/10 | RBC Capital double-upgraded Pfizer from Underperform to Sector Perform, maintaining a $25 price target, which sits rough | Jun 10, 2026 |